Intrinsiqs

Is Mineralys Therapeutics, Inc. overvalued?

Mineralys Therapeutics, Inc. (MLYS) — key valuation metrics and fundamentals.

No verdict
Price
$15.33
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$1.36B
Dividend yield
0.0%
Return on equity
-63.3%
Sector
Healthcare

See the full interactive analysis →

Fair value compares MLYS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.